These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 14562773)

  • 1. [What information is given on adverse drug reactions from new drugs?].
    Eldholm RS; Bergheim TS; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2003 Sep; 123(17):2414-7. PubMed ID: 14562773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Adverse effects--making nail soup].
    Lund H
    Tidsskr Nor Laegeforen; 2003 Oct; 123(20):2918-9; author reply 2919. PubMed ID: 14600727
    [No Abstract]   [Full Text] [Related]  

  • 3. [Adverse effects--making nail soup or nailing the coffin?].
    Reseland S
    Tidsskr Nor Laegeforen; 2003 Dec; 123(24):3628. PubMed ID: 14691529
    [No Abstract]   [Full Text] [Related]  

  • 4. Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions.
    Wysowski DK; Swartz L
    Arch Intern Med; 2005 Jun; 165(12):1363-9. PubMed ID: 15983284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adverse-drug-event data provided by pharmaceutical companies.
    Cudny ME; Graham AS
    Am J Health Syst Pharm; 2008 Jun; 65(11):1071-5. PubMed ID: 18499882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The incidence of drug side effects with reference to organ systems. Experience of the spontaneous reporting system of the Swiss Drug Side Effect Center and Comprehensive Drug Monitoring].
    Kuhn M; Hartmann K; Maibach R; Capaul R; Gartmann JC
    Ther Umsch; 1993 Jan; 50(1):8-12. PubMed ID: 8378869
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Irrational use of drugs as a source of drug - induced diseases].
    Woroń J; Porebski G; Kostka-Trabka E; Goszcz A
    Med Wieku Rozwoj; 2007; 11(2 Pt 1):87-91. PubMed ID: 17625274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Patient reporting of adverse drug reactions in Norway 2010-13].
    Fjermeros K; Werner MC; Harg P; Samdal H; Slørdal L; Spigset O
    Tidsskr Nor Laegeforen; 2015 Mar; 135(6):536-40. PubMed ID: 25806761
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies.
    Spelsberg A; Prugger C; Doshi P; Ostrowski K; Witte T; Hüsgen D; Keil U;
    BMJ; 2017 Feb; 356():j337. PubMed ID: 28174182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Drug Safety Rating System Based on Postmarketing Costs Associated with Adverse Events and Patient Outcomes.
    Hoffman KB; Dimbil M; Kyle RF; Tatonetti NP; Erdman CB; Demakas A; Chen D; Overstreet BM
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1134-43. PubMed ID: 26679963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance and communicating safety information.
    Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug interactions in an intensive care unit].
    Nielsen EW; Dybwik K
    Tidsskr Nor Laegeforen; 2004 Nov; 124(22):2907-8. PubMed ID: 15550963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose discrepancies between the Physicians' Desk Reference and the medical literature, and their possible role in the high incidence of dose-related adverse drug events.
    Cohen JS
    Arch Intern Med; 2001 Apr; 161(7):957-64. PubMed ID: 11295958
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug effects on the liver: a tabular compilation of drugs and drug-related hepatic diseases.
    Ludwig J
    Dig Dis Sci; 1979 Oct; 24(10):785-96. PubMed ID: 487916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The National List of recommendations-- what is it based on?].
    Kampmann JP; Glintborg D; Bygsø MJ
    Ugeskr Laeger; 2009 Mar; 171(10):780-3. PubMed ID: 19265599
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A patient's perspective: the impact of adverse drug reactions on patients and their views on reporting.
    Lorimer S; Cox A; Langford NJ
    J Clin Pharm Ther; 2012 Apr; 37(2):148-52. PubMed ID: 21592157
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Post-approval appending of CSARs to drug package inserts: an analysis of the types of adverse reactions and time to addition.
    Tamura N; Ishiguro C; Matsuda T
    Pharmacoepidemiol Drug Saf; 2015 Feb; 24(2):166-75. PubMed ID: 24737526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pediatric information in drug product labeling.
    Sachs AN; Avant D; Lee CS; Rodriguez W; Murphy MD
    JAMA; 2012 May; 307(18):1914-5. PubMed ID: 22570457
    [No Abstract]   [Full Text] [Related]  

  • 19. Reporting of adverse drug reactions may be influenced by feedback to the reporting doctor.
    Wallerstedt SM; Brunlöf G; Johansson ML; Tukukino C; Ny L
    Eur J Clin Pharmacol; 2007 May; 63(5):505-8. PubMed ID: 17347804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse drug reactions.
    Shuttleworth A
    Nurs Times; 2006 Jul 25-31; 102(30):58. PubMed ID: 16903313
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.